Skip to main content
. Author manuscript; available in PMC: 2011 May 11.
Published in final edited form as: Diabetes Res Clin Pract. 2010 Nov 9;91(1):101–107. doi: 10.1016/j.diabres.2010.07.004

Table 3. Association of African-American race with coronary artery calcification adjusted for age and individual risk factors.

Variable adjusted for Males n = 576 Females n = 285 Allan = 861
Age 0.14 (0.08–0.24) (p < 0.001) 0.26 (0.09–0.77) (p = 0.015) 0.17 (0.11–0.28) (p < 0.001)
Duration of diabetes 0.13 (0.07–0.22) (p < 0.001) 0.25 (0.09–0.73) (p = 0.011) 0.16 (0.10–0.27) (p < 0.001)
HbA1c 0.14 (0.08–0.24) (p < 0.001) 0.26 (0.09–0.76) (p = 0.014) 0.17 (0.10–0.28) (p < 0.001)
Smoking history 0.12 (0.07–0.22) (p < 0.001) 0.26 (0.09–0.74) (p = 0.012) 0.16 (0.10–0.26) (p < 0.001)
Systolic blood pressure 0.13 (0.07–0.23) (p < 0.001) 0.29 (0.10–0.85) (p = 0.025) 0.17 (0.10–0.28) (p < 0.001)
Diastolic blood pressure 0.14 (0.08–0.24) (p < 0.001) 0.27 (0.09–0.80) (p = 0.018) 0.18 (0.11–0.29) (p < 0.001)
Total cholesterol 0.14 (0.08–0.24) (p < 0.001) 0.26 (0.09–0.76) (p = 0.014) 0.17 (0.11–0.28) (p < 0.001)
LDL cholesterol 0.14 (0.08–0.24) (p < 0.001) 0.26 (0.09–0.75) (p = 0.013) 0.18 (0.11–0.29) (p < 0.001)
HDL cholesterol 0.14 (0.08–0.25) (p < 0.001) 0.31 (0.11–0.93) (p = 0.036) 0.19 (0.12–0.31) (p < 0.001)
Triglycerides 0.15 (0.08–0.26) (p < 0.001) 0.48 (0.15–1.49) (p = 0.201) 0.20 (0.12–0.34) (p < 0.001)
VLDL cholesterol 0.14 (0.08–0.25) (p < 0.001) 0.37 (0.12–1.08) (p = 0.068) 0.20 (0.12–0.32) (p < 0.001)
Apolipoprotein A-I 0.14 (0.08–0.24) (p < 0.001) 0.27 (0.09–0.78) (p = 0.016) 0.18 (0.11–0.29) (p < 0.001)
Apolipoprotein A-II 0.13 (0.08–0.24) (p < 0.001) 0.27 (0.09–0.79) (p = 0.017) 0.17 (0.11–028) (p < 0.001)
Apolipoprotein B 0.14 (0.08–0.24) (p < 0.001) 0.27 (0.09–0.80) (p = 0.018) 0.17 (0.11–0.28) (p < 0.001)
Framingham risk score 0.13 (0.08–0.24) (p < 0.001) 0.26 (0.09–0.76) (p = 0.014) 0.17 (0.10–0.28) (p < 0.001)
BMI 0.14 (0.08–0.24) (p < 0.001) 0.27 (0.09–0.78) (p = 0.016) 0.17 (0.11–0.28) (p < 0.001)
Waist circumference 0.15 (0.09–0.26) (p < 0.001) 0.27 (0.09–0.80) (p = 0.018) 0.19 (0.11–0.30) (p < 0.001)
Metabolic syndrome 0.14 (0.08–0.25) (p < 0.001) 0.26 (0.09–0.76) (p = 0.014) 0.18 (0.11–0.30) (p < 0.001)
Leptin 0.14 (0.08–0.24) (p < 0.001) 0.27 (0.09–0.81) (p = 0.020) 0.17 (0.10–0.28) (p < 0.001)
Adiponectin 0.14 (0.08–0.25) (p < 0.001) 0.30 (0.10–0.88) (p = 0.028) 0.19 (0.11–0.31) (p < 0.001)
CRP 0.14 (0.08–0.24) (p < 0.001) 0.24 (0.08–0.69) (p = 0.008) 0.17 (0.10–0.28) (p < 0.001)
IL-6 0.15 (0.08–0.30) (p < 0.001) 0.21 (0.07–0.66) (p = 0.008) 0.18 (0.10–0.33) (p < 0.001)
HOMA2-IR 0.16 (0.09–0.30) (p < 0.001) 0.28 (0.08–1.03) (p = 0.055) 0.20 (0.11–0.35) (p < 0.001)
Alcohol use 0.14 (0.08–0.24) (p < 0.001) 0.33 (0.11–0.97) (p = 0.044) 0.19 (0.11–0.31) (p < 0.001)
Exercise 0.14 (0.08–0.24) (p < 0.001) 0.28 (0.10–0.82) (p = 0.020) 0.17 (0.11–0.28) (p < 0.001)
Post-menopausal 0.25 (0.08–0.73) (p = 0.012)

Results are presented as age-adjusted Tobit ratios (95% confidence intervals) of increase in CAC scores of AA vs. Whites.

a

Adjusted for age and gender.